Visible joint lumps

See Doctor Soon

4 studies · 1 recommendation

Last updated: January 31, 2026

See Doctor Soon4 studies

Visible joint lumps signal severe gout requiring prompt specialist evaluation and stricter treatment

Four studies involving over 2,000 gout patients demonstrate that visible joint lumps (tophi) mark significantly elevated disease burden and complication risk. A case-control study of 1,451 patients found tophi presence in 77% of high-risk cases versus 31% of controls (P=0.003), with 3.4-fold higher mortality risk (95% CI: 1.39-8.48). Patients with tophi require stricter urate targets (<5 mg/dL versus <6 mg/dL), yet only 26% achieve this goal. Two prospective cohort studies totaling 444 patients each revealed tophi independently predict type 2 diabetes development with 2.6-fold increased risk (OR 2.61, 95% CI: 1.50-4.54; p=0.001)—59.3% of patients developing diabetes had tophi compared to 30% who remained diabetes-free. These findings indicate visible lumps warrant timely rheumatology referral for intensified urate-lowering therapy and metabolic screening.

Evidence

Contributing factors of diabetes mellitus among patients with gout (results of the long-term prospective study)

Authors: E. L. Nasonov, M. S. Eliseev, O. V. Zheliabina, S. I. Glukhova

Published: July 1, 2022

Among 444 gout patients without diabetes at baseline, followed prospectively for a median of 5.66 years, the presence of tophi independently predicted development of type 2 diabetes mellitus. Multivariate analysis showed an odds ratio of 2.61 (95% CI: 1.50–4.54; p=0.001) for T2DM in patients with tophi compared to those without. Of the total cohort, 24.3% (108 patients) developed diabetes during follow-up, with tophaceous gout representing a 2.6-fold increased risk.

View Source →

Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study

Authors: M. N. Chikina, M. S. Eliseev, O. V. Zhelyabina, S. I. Glukhova, T. S. Panevin

Published: February 1, 2022

Among 444 gout patients followed prospectively for 2-8 years, subcutaneous tophi were present in 59.3% of patients who developed type 2 diabetes compared to only 30.0% of those who remained diabetes-free (p=0.001). Logistic regression analysis confirmed the presence of tophi as an independent risk factor for developing type 2 diabetes, linking visible evidence of uncontrolled gout to metabolic complications.

View Source →

Patients with severe gout treated in mixed settings

Authors: Larsen, Monica Bak, Linauskas, Asta, Rasmussen, Claus

Published: October 18, 2021

This cohort study of 100 crystal-proven gout patients established that patients with tophi require a stricter plasma urate target of <5 mg/dl (<0.30 mmol/l) compared to <6 mg/dl (<0.36 mmol/l) for patients without tophi. Among 85 surviving patients followed for 24 months, only 26% achieved their target urate level, 39% failed to reach target, and 35% had no urate monitoring. Better outcomes were associated with continued rheumatology clinic care, indicating that tophi presence warrants specialized follow-up.

View Source →

Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality.

Authors: Pedersen, Brian, Sharma, Ena, Terkeltaub, Robert

Published: January 1, 2019

In this retrospective case-control study of 1451 gout patients at a VA rheumatology practice, those with palpable tophi at baseline had significantly elevated serum urate levels (10.6 mg/dL vs 7.6 mg/dL in controls, P < 0.0001). Tophi were present in 10 of 13 patients (77%) in the high-risk group compared to 16 of 52 controls (31%), P = 0.003. Factor analysis identified baseline palpable tophus as the strongest predictor of disease severity. The group with tophi and elevated urate demonstrated higher all-cause mortality (6/13 vs 7/52, relative risk 3.43, 95% CI 1.39-8.48, P = 0.0076), though mortality was attributed more to associated comorbidities than to treatment.

View Source →